메뉴 건너뛰기




Volumn 43, Issue 3, 2014, Pages 215-222

Evolution of interventional vancomycin trials in light of new antibiotic development in the USA, 1999-2012

Author keywords

Antibiotics; Clinical trials; Drug development; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; CEFTAROLINE FOSAMIL; CEFTOBIPROLE MEDOCARIL; DALBAVANCIN; DAPTOMYCIN; FIDAXOMICIN; FUSIDATE SODIUM; ICLAPRIM; LFF 571; LINEZOLID; ORITAVANCIN; PLEUROMUTILIN; RIFAMPICIN; SUROTOMYCIN; TD 1792; TELAVANCIN; TIGECYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN;

EID: 84896495705     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.10.002     Document Type: Review
Times cited : (5)

References (52)
  • 2
    • 84875982804 scopus 로고    scopus 로고
    • The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: A national observational study
    • E.Y. Klein, L. Sun, D.L. Smith, and R. Laxminarayan The changing epidemiology of methicillin-resistant Staphylococcus aureus in the United States: a national observational study Am J Epidemiol 177 2013 666 674
    • (2013) Am J Epidemiol , vol.177 , pp. 666-674
    • Klein, E.Y.1    Sun, L.2    Smith, D.L.3    Laxminarayan, R.4
  • 3
    • 44149113314 scopus 로고    scopus 로고
    • Epidemiology of methicillin-resistant Staphylococcus aureus
    • H.W. Boucher, and G.R. Corey Epidemiology of methicillin-resistant Staphylococcus aureus Clin Infect Dis 46 Suppl 5 2008 S344 S349
    • (2008) Clin Infect Dis , vol.46 , Issue.SUPPL. 5
    • Boucher, H.W.1    Corey, G.R.2
  • 5
    • 29244453639 scopus 로고    scopus 로고
    • Vancomycin: A 50-year reassessment
    • R.C. Moellering Jr. Vancomycin: a 50-year reassessment Clin Infect Dis 42 Suppl 1 2006 S3 S4
    • (2006) Clin Infect Dis , vol.42 , Issue.SUPPL. 1
    • Moellering, Jr.R.C.1
  • 6
    • 29244437540 scopus 로고    scopus 로고
    • Vancomycin: A history
    • D.P. Levine Vancomycin: a history Clin Infect Dis 42 Suppl 1 2006 S5 S12
    • (2006) Clin Infect Dis , vol.42 , Issue.SUPPL. 1
    • Levine, D.P.1
  • 7
    • 62449183879 scopus 로고    scopus 로고
    • Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists
    • M. Rybak, B. Lomaestro, J.C. Rotschafer, R. Moellering Jr., W. Craig, and M. Billeter et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists Am J Health Syst Pharm 66 2009 82 98
    • (2009) Am J Health Syst Pharm , vol.66 , pp. 82-98
    • Rybak, M.1    Lomaestro, B.2    Rotschafer, J.C.3    Moellering, Jr.R.4    Craig, W.5    Billeter, M.6
  • 9
    • 33144473431 scopus 로고    scopus 로고
    • Bad bugs need drugs: An update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America
    • G.H. Talbot, J. Bradley, J.E. Edwards Jr., D. Gilbert, M. Scheld, and J.G. Bartlett Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America Clin Infect Dis 42 2006 657 668
    • (2006) Clin Infect Dis , vol.42 , pp. 657-668
    • Talbot, G.H.1    Bradley, J.2    Edwards, Jr.J.E.3    Gilbert, D.4    Scheld, M.5    Bartlett, J.G.6
  • 11
    • 0033517574 scopus 로고    scopus 로고
    • Time to register randomised trials. The case is now unanswerable
    • R. Horton, and R. Smith Time to register randomised trials. The case is now unanswerable BMJ 319 1999 865 866
    • (1999) BMJ , vol.319 , pp. 865-866
    • Horton, R.1    Smith, R.2
  • 12
    • 0033547647 scopus 로고    scopus 로고
    • Registering clinical trials
    • A. Tonks Registering clinical trials BMJ 319 1999 1565 1568
    • (1999) BMJ , vol.319 , pp. 1565-1568
    • Tonks, A.1
  • 13
    • 29544449337 scopus 로고    scopus 로고
    • Trial registration at ClinicalTrials.gov between May and October 2005
    • D.A. Zarin, T. Tse, and N.C. Ide Trial registration at ClinicalTrials.gov between May and October 2005 N Engl J Med 353 2005 2779 2787
    • (2005) N Engl J Med , vol.353 , pp. 2779-2787
    • Zarin, D.A.1    Tse, T.2    Ide, N.C.3
  • 14
    • 84896491689 scopus 로고    scopus 로고
    • And Drug Administration Amendments Act Of 2007 F.
    • Food and Drug Administration Amendments Act of 2007 Public Law: 110th Congress 2007
    • (2007) Public Law: 110th Congress
  • 15
    • 40449088049 scopus 로고    scopus 로고
    • Medicine. Moving toward transparency of clinical trials
    • D.A. Zarin, and T. Tse Medicine. Moving toward transparency of clinical trials Science 319 2008 1340 1342
    • (2008) Science , vol.319 , pp. 1340-1342
    • Zarin, D.A.1    Tse, T.2
  • 16
    • 79955752771 scopus 로고    scopus 로고
    • Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects
    • J.G. Still, K. Clark, T.P. Degenhardt, D. Scott, P. Fernandes, and M.J. Gutierrez Pharmacokinetics and safety of single, multiple, and loading doses of fusidic acid in healthy subjects Clin Infect Dis 52 Suppl 7 2011 S504 S512
    • (2011) Clin Infect Dis , vol.52 , Issue.SUPPL. 7
    • Still, J.G.1    Clark, K.2    Degenhardt, T.P.3    Scott, D.4    Fernandes, P.5    Gutierrez, M.J.6
  • 17
    • 84866313208 scopus 로고    scopus 로고
    • In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile
    • C.T. Mascio, L.I. Mortin, K.T. Howland, A.D. Van Praagh, S. Zhang, and A. Arya et al. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile Antimicrob Agents Chemother 56 2012 5023 5030
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 5023-5030
    • Mascio, C.T.1    Mortin, L.I.2    Howland, K.T.3    Van Praagh, A.D.4    Zhang, S.5    Arya, A.6
  • 18
    • 84864386108 scopus 로고    scopus 로고
    • Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571
    • J.A. Leeds, M. Sachdeva, S. Mullin, J. Dzink-Fox, and M.J. Lamarche Mechanism of action of and mechanism of reduced susceptibility to the novel anti-Clostridium difficile compound LFF571 Antimicrob Agents Chemother 56 2012 4463 4465
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 4463-4465
    • Leeds, J.A.1    Sachdeva, M.2    Mullin, S.3    Dzink-Fox, J.4    Lamarche, M.J.5
  • 19
    • 84868254408 scopus 로고    scopus 로고
    • Fecal microbiota transplantation in relapsing Clostridium difficile infection
    • F. Rohlke, and N. Stollman Fecal microbiota transplantation in relapsing Clostridium difficile infection Therap Adv Gastroenterol 5 2012 403 420
    • (2012) Therap Adv Gastroenterol , vol.5 , pp. 403-420
    • Rohlke, F.1    Stollman, N.2
  • 20
    • 84857183374 scopus 로고    scopus 로고
    • Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections
    • H.S. Sader, D.J. Biedenbach, S. Paukner, Z. Ivezic-Schoenfeld, and R.N. Jones Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections Antimicrob Agents Chemother 56 2012 1619 1623
    • (2012) Antimicrob Agents Chemother , vol.56 , pp. 1619-1623
    • Sader, H.S.1    Biedenbach, D.J.2    Paukner, S.3    Ivezic-Schoenfeld, Z.4    Jones, R.N.5
  • 23
    • 0242291985 scopus 로고    scopus 로고
    • Why is big Pharma getting out of antibacterial drug discovery?
    • S.J. Projan Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6 2003 427 430
    • (2003) Curr Opin Microbiol , vol.6 , pp. 427-430
    • Projan, S.J.1
  • 25
    • 12944302098 scopus 로고    scopus 로고
    • Lack of development of new antimicrobial drugs: A potential serious threat to public health
    • European Society of Clinical Microbiology and Infectious Diseases
    • S.R. Norrby, C.E. Nord, R. Finch European Society of Clinical Microbiology and Infectious Diseases Lack of development of new antimicrobial drugs: a potential serious threat to public health Lancet Infect Dis 5 2005 115 119
    • (2005) Lancet Infect Dis , vol.5 , pp. 115-119
    • Norrby, S.R.1    Nord, C.E.2    Finch, R.3
  • 26
    • 2342534392 scopus 로고    scopus 로고
    • Development of drugs for antimicrobial-resistant pathogens
    • J.H. Powers Development of drugs for antimicrobial-resistant pathogens Curr Opin Infect Dis 16 2003 547 551
    • (2003) Curr Opin Infect Dis , vol.16 , pp. 547-551
    • Powers, J.H.1
  • 27
    • 84878297844 scopus 로고    scopus 로고
    • Is it time to replace vancomycin in the treatment of methicillin- resistant Staphylococcus aureus infections?
    • S.J. van Hal, and V.G. Fowler Jr. Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 56 2013 1779 1788
    • (2013) Clin Infect Dis , vol.56 , pp. 1779-1788
    • Van Hal, S.J.1    Fowler, Jr.V.G.2
  • 28
    • 84855484682 scopus 로고    scopus 로고
    • New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance
    • I.M. Gould, M.Z. David, S. Esposito, J. Garau, G. Lina, and T. Mazzei et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance Int J Antimicrob Agents 39 2012 96 104
    • (2012) Int J Antimicrob Agents , vol.39 , pp. 96-104
    • Gould, I.M.1    David, M.Z.2    Esposito, S.3    Garau, J.4    Lina, G.5    Mazzei, T.6
  • 29
    • 70349934707 scopus 로고    scopus 로고
    • Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections
    • S. Deresinski Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections Clin Infect Dis 49 2009 1072 1079
    • (2009) Clin Infect Dis , vol.49 , pp. 1072-1079
    • Deresinski, S.1
  • 33
    • 70049105657 scopus 로고    scopus 로고
    • Bad bugs, no drugs: No ESCAPE revisited
    • L.R. Peterson Bad bugs, no drugs: no ESCAPE revisited Clin Infect Dis 49 2009 992 993
    • (2009) Clin Infect Dis , vol.49 , pp. 992-993
    • Peterson, L.R.1
  • 34
    • 84878278251 scopus 로고    scopus 로고
    • 10 × '20 progress - Development of new drugs active against Gram-negative bacilli: An update from the Infectious Diseases Society of America
    • H.W. Boucher, G.H. Talbot, D.K. Benjamin Jr., J. Bradley, R.J. Guidos, and R.N. Jones et al. 10 × '20 progress - development of new drugs active against Gram-negative bacilli: an update from the Infectious Diseases Society of America Clin Infect Dis 56 2013 1685 1694
    • (2013) Clin Infect Dis , vol.56 , pp. 1685-1694
    • Boucher, H.W.1    Talbot, G.H.2    Benjamin, Jr.D.K.3    Bradley, J.4    Guidos, R.J.5    Jones, R.N.6
  • 35
    • 77950255824 scopus 로고    scopus 로고
    • The 10 × '20 Initiative: Pursuing a global commitment to develop 10 new antibacterial drugs by 2020
    • Diseases Society Of America I.
    • Infectious Diseases Society of America The 10 × '20 Initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020 Clin Infect Dis 50 2010 1081 1083
    • (2010) Clin Infect Dis , vol.50 , pp. 1081-1083
  • 36
    • 84896494408 scopus 로고    scopus 로고
    • Nabriva Therapeutics Vienna, Austria
    • ® [Phase II] 2013 Nabriva Therapeutics Vienna, Austria
    • (2013) ® [Phase II]
  • 37
    • 84856718514 scopus 로고    scopus 로고
    • Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection
    • A.A. Venugopal, and S. Johnson Fidaxomicin: a novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection Clin Infect Dis 54 2012 568 574
    • (2012) Clin Infect Dis , vol.54 , pp. 568-574
    • Venugopal, A.A.1    Johnson, S.2
  • 39
    • 0031729229 scopus 로고    scopus 로고
    • The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
    • S.M. Swaney, H. Aoki, M.C. Ganoza, and D.L. Shinabarger The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria Antimicrob Agents Chemother 42 1998 3251 3255
    • (1998) Antimicrob Agents Chemother , vol.42 , pp. 3251-3255
    • Swaney, S.M.1    Aoki, H.2    Ganoza, M.C.3    Shinabarger, D.L.4
  • 40
    • 84896489971 scopus 로고    scopus 로고
    • Tolevamer less effective than standard therapies for C. Difficile-associated diarrhea
    • C. Berrie Tolevamer less effective than standard therapies for C. difficile-associated diarrhea Medscape Medical News April 24, 2008
    • (2008) Medscape Medical News
    • Berrie, C.1
  • 41
    • 84856969539 scopus 로고    scopus 로고
    • Fecal microbiota transplantation and emerging applications
    • T.J. Borody, and A. Khoruts Fecal microbiota transplantation and emerging applications Nat Rev Gastroenterol Hepatol 9 2012 88 96
    • (2012) Nat Rev Gastroenterol Hepatol , vol.9 , pp. 88-96
    • Borody, T.J.1    Khoruts, A.2
  • 42
    • 77953558104 scopus 로고    scopus 로고
    • Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus
    • K.M. Itani, M.S. Dryden, H. Bhattacharyya, M.J. Kunkel, A.M. Baruch, and J.A. Weigelt Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be caused by methicillin-resistant Staphylococcus aureus Am J Surg 199 2010 804 816
    • (2010) Am J Surg , vol.199 , pp. 804-816
    • Itani, K.M.1    Dryden, M.S.2    Bhattacharyya, H.3    Kunkel, M.J.4    Baruch, A.M.5    Weigelt, J.A.6
  • 43
    • 84856937734 scopus 로고    scopus 로고
    • Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: A randomized, controlled study
    • R.G. Wunderink, M.S. Niederman, M.H. Kollef, A.F. Shorr, M.J. Kunkel, and A. Baruch et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study Clin Infect Dis 54 2012 621 629
    • (2012) Clin Infect Dis , vol.54 , pp. 621-629
    • Wunderink, R.G.1    Niederman, M.S.2    Kollef, M.H.3    Shorr, A.F.4    Kunkel, M.J.5    Baruch, A.6
  • 44
    • 13444257356 scopus 로고    scopus 로고
    • Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens
    • I. Raad, R. Darouiche, J. Vazquez, A. Lentnek, R. Hachem, and H. Hanna et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by Gram-positive pathogens Clin Infect Dis 40 2005 374 380
    • (2005) Clin Infect Dis , vol.40 , pp. 374-380
    • Raad, I.1    Darouiche, R.2    Vazquez, J.3    Lentnek, A.4    Hachem, R.5    Hanna, H.6
  • 45
    • 84896494385 scopus 로고    scopus 로고
    • Pharmaceuticals For Children Act Of 2007 B.
    • Best Pharmaceuticals for Children Act of 2007 Public Law: 110th Congress 2007
    • (2007) Public Law: 110th Congress
  • 46
    • 84896494664 scopus 로고    scopus 로고
    • Research Equity Act Of 2007 P.
    • Pediatric Research Equity Act of 2007 Public Law: 110th Congress 2007
    • (2007) Public Law: 110th Congress
  • 49
    • 84864497515 scopus 로고    scopus 로고
    • Pediatric versus adult drug trials for conditions with high pediatric disease burden
    • F.T. Bourgeois, S. Murthy, C. Pinto, K.L. Olson, J.P. Ioannidis, and K.D. Mandl Pediatric versus adult drug trials for conditions with high pediatric disease burden Pediatrics 130 2012 285 292
    • (2012) Pediatrics , vol.130 , pp. 285-292
    • Bourgeois, F.T.1    Murthy, S.2    Pinto, C.3    Olson, K.L.4    Ioannidis, J.P.5    Mandl, K.D.6
  • 50
    • 79952094973 scopus 로고    scopus 로고
    • The quality of registration of clinical trials
    • R.F. Viergever, and D. Ghersi The quality of registration of clinical trials PLoS One 6 2011 e14701
    • (2011) PLoS One , vol.6 , pp. 14701
    • Viergever, R.F.1    Ghersi, D.2
  • 51
    • 3142559736 scopus 로고    scopus 로고
    • Determining the reporting quality of RCTs in clinical pharmacology
    • Erratum in: Br J Clin Pharmacol 2004;58:102
    • E. Mills, Y.K. Loke, P. Wu, V.M. Montori, D. Perri, and D. Moher et al. Determining the reporting quality of RCTs in clinical pharmacology Br J Clin Pharmacol 58 2004 61 65 Erratum in: Br J Clin Pharmacol 2004;58:102
    • (2004) Br J Clin Pharmacol , vol.58 , pp. 61-65
    • Mills, E.1    Loke, Y.K.2    Wu, P.3    Montori, V.M.4    Perri, D.5    Moher, D.6
  • 52
    • 79952267051 scopus 로고    scopus 로고
    • The ClinicalTrials.gov results database - Update and key issues
    • D.A. Zarin, T. Tse, R.J. Williams, R.M. Califf, and N.C. Ide The ClinicalTrials.gov results database - update and key issues N Engl J Med 364 2011 852 860
    • (2011) N Engl J Med , vol.364 , pp. 852-860
    • Zarin, D.A.1    Tse, T.2    Williams, R.J.3    Califf, R.M.4    Ide, N.C.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.